Price: R1,890 (incl. VAT)
Strength: 4mg/0.6ml (3ml pen) – 20mg total
Approx. doses: 20 doses at 1mg (men) or 10 doses at 2mg (women)
What it is
PT-141 (bremelanotide) is a 7-amino-acid peptide that works on the melanocortin receptors in the brain, the centres that drive desire and arousal. Unlike Viagra-type tablets, which act on blood flow, PT-141 works on the nervous system, so it supports desire itself and is used by both men and women. It is used for low libido, arousal difficulties and erectile dysfunction. Each prefilled pen holds 20mg: 20 doses for men or 10 doses for women.
Used for
- Low libido and reduced sexual desire, in men and women
- Arousal difficulties
- Erectile dysfunction, including when tablets have not worked
- Sexual wellness and performance
- Use as needed, about 45 minutes before intimacy
PT-141, also called bremelanotide, is a 7-amino-acid peptide that works on melanocortin receptors in the brain involved in sexual desire and arousal. Bremelanotide is the active ingredient of Vyleesi, approved in the USA for low sexual desire in premenopausal women.
Viagra-type tablets (PDE-5 inhibitors) increase blood flow and only work once you are aroused. PT-141 acts on the nervous system, so it supports desire itself, and it can be used by both men and women.
It is injected under the skin about 45 minutes before intimacy, as needed. On the mobivIVe pen the usual dose is 15 clicks (1mg) for men and 30 clicks (2mg) for women. Never use more than one dose in 24 hours, or more than eight doses a month.
The most common are nausea, which usually eases with later doses, facial flushing or warmth, and headache. PT-141 can cause a small, short rise in blood pressure for a few hours after a dose, which is why it is not suitable with uncontrolled high blood pressure or heart disease.
At mobivIVe, doctor-reviewed PT-141 is R1,890 per prefilled pen, delivered nationwide. One pen holds 20 doses for men or 10 for women. Yes, it is dispensed on a valid medical script after a questionnaire reviewed by our registered doctor, with a consultation arranged when your screening calls for one.